quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

Stocks Recover on Fed Rate Cut Expectations

View original at nasdaq.com
Stocks Recover on Fed Rate Cut Expectations The S&P 500 Index ($SPX) (SPY) today is up by +0.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.06%…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • He will announce his selection for the new Fed Chair in early 2026

    80% confidence
  • Q3 adjusted EPS forecasted at 40 cents, above consensus of 37 cents

    80% confidence
  • Upgraded Vertex Pharmaceuticals to overweight from equal weight with price target of $516

    80% confidence
  • Forecasted Q4 operating income of $220 million to $230 million, above consensus of $214.5 million

    80% confidence
  • Upgraded Stellantis to buy from neutral with price target of $12

    80% confidence
  • Kevin Hassett is seen as the likely choice to succeed Powell as Fed Chair

    80% confidence
  • Q3 earnings rose 14.6%, more than doubling expectations of 7.2% y/y

    80% confidence
  • Microsoft is reducing its AI software sales quotas amid consumer resistance to newer products

    80% confidence
  • 83% of reporting S&P 500 companies exceeded forecasts, on course for the best quarter since 2021

    80% confidence
  • Raised 2026 comparable sales growth forecast to low single digits from previous estimate of flat

    80% confidence
  • Cut full-year adjusted EPS forecast to $1.94-$2.04 from previous estimate of $2.35-$2.45, well below consensus of $2.37

    80% confidence
  • Upgraded Astera Labs to buy with price target of $275

    80% confidence
  • Forecasted Q4 revenue of $251 million to $252 million, midpoint below consensus of $251.9 million

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com